Background

  • Riverpoint Medical (Riverpoint) is a leading developer, designer and manufacturer of medical devices, focused on advanced surgical fiber and regenerative technologies
  • Riverpoint’s offering includes implants, high strength fiber solutions, and proprietary surgical coatings for the sports medicine, orthopedic, wound closure, and cardiovascular markets
  • Riverpoint is a portfolio company of Arlington Capital Partners (Arlington), a Washington, DC-area-based private equity firm with $8 billion+ in AUM. Arlington is focused on middle market investment opportunities in industries such as Healthcare, Aerospace & Defense, Government Services & Technology, and Business Services & Software
  • For over 20 years, CP Medical has been a leading device manufacturer focused on specialty surgical applications and wound closure products for the surgical and animal health markets

Process

  • DC Advisory was exclusively engaged to advise Arlington and its portfolio company, Riverpoint on the acquisition of CP Medical

Outcome

  • CP Medical brings a portfolio of specialty surgical and animal health wound closure devices, including resorbable and non-absorbable products, which are complementary to Riverpoint’s existing capabilities and offerings
  • Riverpoint’s product development and engineering resources also broaden CP Medical’s existing product portfolio
  • This transaction demonstrates DC Advisory’s deep sector expertise and strengthens its existing credentials in the Healthcare sector